Clinical Trial Update: Long Term Protection by and Persistence of Vi Antibodies Induced by Vi-rEPA Conjugate Vaccines in Vietnamese Children Injected at 2-5 Years or at 5-8 Years of Age

View source ↗

Summary

A completed trial in Vietnamese children assessed long-term antibody persistence and protection afforded by the Vi-rEPA conjugate typhoid vaccine given at ages …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Typhoid Fever

Drugs mentioned

• Vi-rEPA conjugate vaccine (Vi-rEPA conjugate vaccine)

Snippet

Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Conditions: Typhoid Fever | Status: COMPLETED